Ovarian Cancer

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

The results of a small clinical trial showed that low-level expression of a microRNA correlated with improved progression-free survival

Nektar Therapeutics announced that its oncology drug candidate, NKTR-102, has been granted orphan drug status

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Cervical cancer affects about 470,000 women each year and now the disease has a new tool to combat its spread

Useful Online Resources and Clinical Trials for Ovarian Cancer

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

Useful Online Resources and Clinical Trials for Ovarian Cancer

The University of Glasgow will begin offering medical and scientific research findings, including cancer-related discoveries, to businesses and entrepreneurs free of charge

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.